An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...

A new draft guidance document quietly issued last week by the US Food and Drug Administration (FDA) is intended to explain how medical device manufacturers can show their devices are safe for use in ...

The European Medicines Agency (EMA) has announced the release of a new concept paper regarding the extrapolation of an experimental drug product's safety and efficacy data to other subgroups, ...